Assurity MRI / Endurity MRI Pacemakers
ABBOTT MEDICAL · Decision date Jul 21, 2026
What did the FDA approve?
FDA records P140033/S101 as a supplement to PMA P140033, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Jul 21, 2026.
FDA approval order statement
approval for Merlin 2 Patient Care System (PCS) programmer support for the AVEIR Leadless Pacemakers.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Cardiovascular
- Decision date
- Jul 21, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P140033/S101
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- LWP
- Decision code
- APPR
- Decision date
- Jul 21, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implantable pulse generator, pacemaker (non-CRT).
- Applicant
- Abbott Medical
- Product code
- LWP
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P140033/S100 · Related supplement
Tendril MRI Pacing Leads / Assurity MRI, Endurity MRI, Zenex MRI, Zenus MRI Pacemakers
P140033/S101 received
Application receipt date recorded by FDA.
P140033/S102 · Related supplement
Assurity MRI, Endurity MRI family of Pacemakers
P140033/S101 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P140033. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P140033
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Nov 20, 2025 | FDA | |
Assurity MRI, Endurity MRI family of PacemakersP140033/S102 | ABBOTT MEDICAL | PMA supplement | Apr 24, 2026 | FDA |
Explore the linked device profile
Other records with product code LWP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA supplement | Oct 29, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 23, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 5, 2026 | FDA | |
| Boston Scientific Corp | PMA supplement | Oct 3, 2026 | FDA | |
| Boston Scientific | PMA supplement | Oct 3, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 15900 Valley View Ct., Sylmar, CA, 91335
Sources and methodology
- Original FDA record: P140033/S101
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


